The SynCardia temporary total artificial heart-evolving clinical role and future status

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The SynCardia Temporary Total Artificial Heart (TAH) is the only clinically effective, Conformité Européene (CE) registered, Food and Drug Administration (FDA) approved and Centers for Medicare and Medicaid Services (CMS) reimbursed total artificial heart system available in the world today. The TAH is a complete, robust, pulsatile, biventricular replacement system indicated for use as a bridge to transplantation in cardiac transplant candidates at risk of imminent death from non-reversible biventricular failure. The TAH offers several advantages relative to present continuous flow left ventricular assist devices (LVADs), including higher 'quality' flow rates, reduced afterload and preload sensitivity, reduced thrombosis and stroke rates, and freedom from device-induced bleeding. More than 900 TAHs have been implanted to date, with a bridge-to-transplant success rate >79%. The availability of the new portable Freedom® driver has significantly enhanced patient mobility and made home discharge of patients possible. With home discharge, significant experience with long-term support on the TAH is now beginning to be accumulated. Technological advances continue to be imparted to the TAH system including portable driver enhancements, remote monitoring, and next-generation TAH designs.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalUS Cardiology
Volume8
Issue number1
StatePublished - 2011

Fingerprint

Artificial Heart
Transplants
Centers for Medicare and Medicaid Services (U.S.)
Heart-Assist Devices
Patient Discharge
United States Food and Drug Administration
Heart Transplantation
Thrombosis
Stroke
Hemorrhage
Equipment and Supplies

Keywords

  • Blood flow
  • Cardiac transplantation
  • Heart failure
  • Mechanical circulatory support
  • Pulsatility
  • Total artificial heart

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The SynCardia temporary total artificial heart-evolving clinical role and future status. / Slepian, Marvin J.

In: US Cardiology, Vol. 8, No. 1, 2011, p. 39-46.

Research output: Contribution to journalArticle

@article{f09ed5db88214f6f9f7c9fea07675b1f,
title = "The SynCardia temporary total artificial heart-evolving clinical role and future status",
abstract = "The SynCardia Temporary Total Artificial Heart (TAH) is the only clinically effective, Conformit{\'e} Europ{\'e}ene (CE) registered, Food and Drug Administration (FDA) approved and Centers for Medicare and Medicaid Services (CMS) reimbursed total artificial heart system available in the world today. The TAH is a complete, robust, pulsatile, biventricular replacement system indicated for use as a bridge to transplantation in cardiac transplant candidates at risk of imminent death from non-reversible biventricular failure. The TAH offers several advantages relative to present continuous flow left ventricular assist devices (LVADs), including higher 'quality' flow rates, reduced afterload and preload sensitivity, reduced thrombosis and stroke rates, and freedom from device-induced bleeding. More than 900 TAHs have been implanted to date, with a bridge-to-transplant success rate >79{\%}. The availability of the new portable Freedom{\circledR} driver has significantly enhanced patient mobility and made home discharge of patients possible. With home discharge, significant experience with long-term support on the TAH is now beginning to be accumulated. Technological advances continue to be imparted to the TAH system including portable driver enhancements, remote monitoring, and next-generation TAH designs.",
keywords = "Blood flow, Cardiac transplantation, Heart failure, Mechanical circulatory support, Pulsatility, Total artificial heart",
author = "Slepian, {Marvin J}",
year = "2011",
language = "English (US)",
volume = "8",
pages = "39--46",
journal = "US Cardiology Review",
issn = "1758-3896",
publisher = "Touch Briefings",
number = "1",

}

TY - JOUR

T1 - The SynCardia temporary total artificial heart-evolving clinical role and future status

AU - Slepian, Marvin J

PY - 2011

Y1 - 2011

N2 - The SynCardia Temporary Total Artificial Heart (TAH) is the only clinically effective, Conformité Européene (CE) registered, Food and Drug Administration (FDA) approved and Centers for Medicare and Medicaid Services (CMS) reimbursed total artificial heart system available in the world today. The TAH is a complete, robust, pulsatile, biventricular replacement system indicated for use as a bridge to transplantation in cardiac transplant candidates at risk of imminent death from non-reversible biventricular failure. The TAH offers several advantages relative to present continuous flow left ventricular assist devices (LVADs), including higher 'quality' flow rates, reduced afterload and preload sensitivity, reduced thrombosis and stroke rates, and freedom from device-induced bleeding. More than 900 TAHs have been implanted to date, with a bridge-to-transplant success rate >79%. The availability of the new portable Freedom® driver has significantly enhanced patient mobility and made home discharge of patients possible. With home discharge, significant experience with long-term support on the TAH is now beginning to be accumulated. Technological advances continue to be imparted to the TAH system including portable driver enhancements, remote monitoring, and next-generation TAH designs.

AB - The SynCardia Temporary Total Artificial Heart (TAH) is the only clinically effective, Conformité Européene (CE) registered, Food and Drug Administration (FDA) approved and Centers for Medicare and Medicaid Services (CMS) reimbursed total artificial heart system available in the world today. The TAH is a complete, robust, pulsatile, biventricular replacement system indicated for use as a bridge to transplantation in cardiac transplant candidates at risk of imminent death from non-reversible biventricular failure. The TAH offers several advantages relative to present continuous flow left ventricular assist devices (LVADs), including higher 'quality' flow rates, reduced afterload and preload sensitivity, reduced thrombosis and stroke rates, and freedom from device-induced bleeding. More than 900 TAHs have been implanted to date, with a bridge-to-transplant success rate >79%. The availability of the new portable Freedom® driver has significantly enhanced patient mobility and made home discharge of patients possible. With home discharge, significant experience with long-term support on the TAH is now beginning to be accumulated. Technological advances continue to be imparted to the TAH system including portable driver enhancements, remote monitoring, and next-generation TAH designs.

KW - Blood flow

KW - Cardiac transplantation

KW - Heart failure

KW - Mechanical circulatory support

KW - Pulsatility

KW - Total artificial heart

UR - http://www.scopus.com/inward/record.url?scp=79956337203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956337203&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79956337203

VL - 8

SP - 39

EP - 46

JO - US Cardiology Review

JF - US Cardiology Review

SN - 1758-3896

IS - 1

ER -